PPARα agonists, such as fenofibrate and bezafibrate, are widely used to treat dyslipidemia, preventing hepatic steatosis and improving insulin sensitivity (Chou et al., 2002; Harano et al., 2006). Here, PPARA is linked to metabolic syndrome.